Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Nov
18
Today In Oncology
My 50 Years in Lymphoma: Lessons Learned?
Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma
Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer
Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo